Uncategorized

Biopharma layoffs must double in H2 for 2026 to match 2025 cuts

Published

on

With fewer biopharmas making or planning workforce reductions so far year over year, layoff round size and M&A impact on headcounts will likely shape the number of employees who are ultimately on the chopping block.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version